Jordan Sloshower, MD, MSc
Clinical Instructor of PsychiatryCards
About
Research
Publications
Featured Publications
Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees
Prueitt WL, Sloshower J. Psychedelic Medicine: Creating an Introductory Course for Mental Health Professionals and Trainees. Academic Psychiatry 2022, 47: 74-77. PMID: 35616783, PMCID: PMC9134971, DOI: 10.1007/s40596-022-01662-9.Peer-Reviewed Original ResearchResearch abuses against people of colour and other vulnerable groups in early psychedelic research
Strauss D, de la Salle S, Sloshower J, Williams MT. Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal Of Medical Ethics 2021, 48: 728-737. PMID: 34253622, DOI: 10.1136/medethics-2021-107262.Peer-Reviewed Original ResearchSubstance use disordersDrug administration conditionsPsychedelic researchMental health issuesEthnicity of participantsUse disordersMental healthHealth issuesVulnerable populationsPsychedelic medicineVulnerable groupsResearch abusesFuture studiesAdministration conditionsAbuseCurrent ethical standardsFirst waveVariables of interestParticipantsFindingsPsilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
Sloshower J, Guss J, Krause R, Wallace R, Williams M, Reed S, Skinta M. Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal Of Contextual Behavioral Science 2020, 15: 12-19. DOI: 10.1016/j.jcbs.2019.11.002.Peer-Reviewed Original ResearchMajor depressive disorderClinical trialsDepressive disorderPsychedelic-assisted therapyPsilocybin-assisted therapyCommitment TherapyRecent clinical trialsSmall clinical trialsDosing sessionsNeurobiological actionsPsilocybin therapyEvidence-based modelTherapyTherapy protocolsPsilocybin experiencePotential synergismDrug experienceTherapy sessionsTreatment modelClinical processesTrialsDisordersPsychological flexibilityMechanisms of changeACT processesIntegrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic
Sloshower J. Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic. 2018, 113-132. DOI: 10.1007/978-3-319-76720-8_7.ChaptersHealing paradigmPsychiatric practiceCurrent psychiatric practicePsychedelic substancesSymptom-focused treatmentEthical challengesReductionist tendenciesCritical dialogueHuman beingsPsychedelic medicineReflexive mannerModel clinicTherapeutic narrativesMental illnessParadigm integrationBiological paradigmMedical SciencesSufferingRelated practicesKnowledge generationPassive recipientsPracticeEnergetic domainsSuch challengesParadigmNeuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reportsPsilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Sloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntidepressant effectsDepressive disorderSevere major depressive disorderPsilocybin-assisted therapyEarly phase studiesQuality of lifeClinical improvementDosing sessionsMajor depressionPsilocybin administrationPlacebo effectPsychotherapeutic supportPlaceboTherapy effectsStudy periodPsychotherapy studiesFurther studiesSignificant differencesDepressionDosingTherapyHigh rateEffect sizeDegree of changeSub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms
Skosnik P, Sloshower J, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal Of Psychopharmacology 2023, 37: 687-697. PMID: 37392016, DOI: 10.1177/02698811231179800.Peer-Reviewed Original ResearchConceptsAntidepressant effectsTheta powerMajor depressive disorderEffects of psilocybinSub-acute effectsLong-term alterationsMeasures of depressionSingle doseDepressive disorderMajor depressionDepressive symptomsPlaceboSymptoms 2Depression symptomsEEG theta powerNeural plasticityNeuroplasticityEEG biomarkersSymptomsSerotonergic psychedelicsPotential mechanismsDepressionSustained changesElectroencephalographic correlatesPsilocybinThe DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate B, Ermakova A, Sloshower J, Galvão-Coelho N, Palhano-Fontes F, Antunes H, Loures de Assis G, Cavnar C, de Araújo D, Ribeiro S. The DEA report on ayahuasca risks: “Science” in service of prohibition? Journal Of Psychedelic Studies 2023, 7: 81-89. DOI: 10.1556/2054.2023.00279.Peer-Reviewed Original ResearchSingle-Dose Psilocybin Treatment for Major Depressive Disorder
Raison C, Sanacora G, Woolley J, Heinzerling K, Dunlop B, Brown R, Kakar R, Hassman M, Trivedi R, Robison R, Gukasyan N, Nayak S, Hu X, O’Donnell K, Kelmendi B, Sloshower J, Penn A, Bradley E, Kelly D, Mletzko T, Nicholas C, Hutson P, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis M, Nelson-Douthit C, Wilson S, Brown C, Linton W, Johnson M, Ross S, Griffiths R. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA 2023, 330: 843-853. PMID: 37651119, PMCID: PMC10472268, DOI: 10.1001/jama.2023.14530.Peer-Reviewed Original ResearchConceptsMajor depressive disorderSheehan Disability Scale scoresAdverse eventsDisability scale scorePsilocybin treatmentDay 43Scale scoreSecondary outcomesSingle doseDepressive disorderExclusion criteriaPsychological supportMontgomery-Asberg Depression Rating Scale scoreSerious treatment-emergent adverse eventsDay 8Key secondary outcome measuresTreatment-emergent adverse eventsDepression Rating Scale scoresActive substance use disorderFifth Edition diagnosisIdentical-appearing capsulesOverall adverse eventsPhase 2 trialSerious adverse eventsSevere adverse events
2024
Letter to the Editors.
Guss J, Sloshower J. Letter to the Editors. Psychodynamic Psychiatry 2024, 52: 237-238. PMID: 38829229, DOI: 10.1521/pdps.2024.52.2.237.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- April 23, 2024Source: Scientific Reports
Psychological Flexibility as a Mechanism of Change in Psilocybin-Assisted Therapy for Major Depression: Results From an Exploratory Placebo-Controlled Trial
- June 20, 2023Source: New Haven Independent
Whalley Wellness Center Explores Therapy’s Frontier
- March 24, 2023Source: Journal of Psychopharmacology
Psilocybin-Assisted Therapy for Major Depressive Disorder: An Exploratory Placebo-Controlled, Fixed-Order Trial
- June 16, 2022
Sloshower Elected to Founding Board of Directors of American Psychedelic Practitioners Association